Vantage Consulting Group’s Amedisys AMED Stock Holding History

Vantage Consulting Group’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-52	Closed	-$15K	–	175
2020 Q4	$15K	Buy	+52	New	+$13.3K	﹤0.01%	1002

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vantage Consulting Group's AMED Position: Q1 2021 in Review

Vantage Consulting Group sold out of Amedisys (AMED) in Q1 2021, closing a stake of 52 shares — an estimated $15K sold.

Vantage Consulting Group first reported a position in AMED in Q4 2020 and held it in 1 quarter. The position peaked at $15K in Q4 2020. 388 funds tracked by Wall St. Rank hold AMED as of Q1 2021.

Vantage Consulting Group reported no remaining Amedisys position as of Q1 2021 after selling out during the quarter.
Vantage Consulting Group sold 52 Amedisys shares in Q1 2021, an estimated $15K.
Vantage Consulting Group first reported a position in Amedisys in Q4 2020 and held it in 1 quarter.
Vantage Consulting Group's Amedisys position peaked at $15K in Q4 2020.
388 funds tracked by Wall St. Rank held Amedisys as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.